Role of Calcitonin Gene-Related Peptide in Nociceptive Modulation in Anterior Cingulate Cortex of Naïve Rats and Rats With Inflammatory Pain

Ke-Sai Hou¹, Lin-Lin Wang¹, Hong-Bo Wang¹, Feng-Hua Fu¹* and Long-Chuan Yu¹,2*

¹ School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China, ² Neurobiology Laboratory, School of Life Sciences, Peking University, Beijing, China

It is known that calcitonin gene-related peptide (CGRP) plays a key role in pain modulation in the brain. There are high expressions of CGRP and CGRP receptor in anterior cingulate cortex (ACC), an important brain structure in pain modulation. The present study explored the role and mechanisms of CGRP and CGRP receptor in nociceptive modulation in ACC in naïve rats and inflammatory rats. Administration of different doses of CGRP in ACC induced significant antinociception in a dose-dependent manner in both naïve rats and rats with inflammatory pain. The CGRP-induced antinociception was attenuated by injection of the CGRP receptor antagonist CGRP8-37 in ACC. Interestingly, both CGRP-induced antinociception and CGRP receptor expression decreased in ACC in rats with inflammatory pain compared with naïve rats. Knockdown of CGRP receptor in ACC by siRNA targeting to CGRP receptor attenuated both the CGRP receptor expression and the CGRP-induced antinociception significantly in rats. These findings demonstrate that CGRP and CGRP receptor participate in nociceptive modulation in ACC, inhibiting CGRP receptor expression induces decrease in CGRP-induced antinociception in ACC.

Keywords: anterior cingulate cortex (ACC), antinociception, calcitonin gene-related peptide (CGRP), CGRP8-37, inflammatory pain, small interfering RNA (siRNA)

INTRODUCTION

In clinic, inflammatory pain is one of the common chronic pain (Zhuo, 2008; Li S. et al., 2017; Tomic et al., 2018). ACC is a cortical region for pain modulation, such as chronic pain (Zhuo, 2006; Xu et al., 2008; Li et al., 2010; Gu et al., 2015; Shen et al., 2015; Bliss et al., 2016; Lu et al., 2016; Tsuda et al., 2017; Zhang et al., 2017a; Zhang et al., 2017b; Li et al., 2019). Recent study showed that
long-term potentiation is a key cellular mechanism for chronic pain in the ACC (Li et al., 2019). It has been reported that ACC is involved in nociceptive modulation in acute and chronic inflammation (Bliss et al., 2016; Harris-Bozer and Peng, 2016; Zhang et al., 2017a). Zhang and her colleagues reported that galanin produced antinociceptive effect in ACC in inflammatory rats (Zhang et al., 2017a). Wang and her colleagues found that mu opioid receptor contributed to nociceptive modulation in ACC in rats with inflammatory pain (Wang et al., 2019).

CGRP is a peptide which has 37-amino acid, and distributed diffusely in nervous system (Rosenfeld et al., 1983; Maggi, 1995; Russell et al., 2014). A lot of studies showed that CGRP and CGRP receptor participate in the modulation and/or transmission of pain information in peripheral and central nervous system (Yu et al., 2003; Edvinsson, 2008; Yu et al., 2009; Han et al., 2010; Bullock and Kelly, 2013; Edvinsson, 2017; Hay and Walker, 2017; Iyengar et al., 2017; Tepper, 2019). CGRP binds CGRP receptor to play physiological function. Now it is found that the functional CGRP receptor is composed of three different protein molecules, calcitonin receptor-like receptor (CLR), receptor activity modifying protein 1, and receptor component protein, and CLR is the main component of CGRP receptor (Yu et al., 2009; Wang Y. et al., 2016; Hay and Walker, 2017).

Interestingly, in situ hybridization and immunohistochemistry studies have demonstrated that CGRP and CGRP receptors are expressed in ACC (Li et al., 2019; Warfvinge and Edvinsson, 2019). The role of CGRP and CGRP receptor in pain regulation in the ACC in naïve rats and rats with inflammatory pain is worth exploring.

### METHODS

#### Experimental Animals

The adult Sprague-Dawley rats (age: 6–7 weeks; male; weighing 200–230g; Jinan Pengyue Laboratory Animal Breeding Co. Ltd, Jinan, China) were used in the study. Animals were kept in individual plastic cages with free access to water and food under an artificial light/dark cycle (12 h in the light, 12 h in the dark), and with room temperature (22–24°C). All experimental procedures and animal care complied with the principles outlined in the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Yantai University (the authorization number is YTU20180124). Animal studies are reported in compliance with The ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015).

#### The Hot Plate Tests

Before experiments, rats received behavioral test training. Each rat was tested with thermal stimulation. The hindpaw withdrawal latency (HWL) of rats to noxious thermal stimulations was measured (Sun et al., 2003; Li et al., 2005; Li S. Y. et al., 2017). The hot plate (YLS-6B Intelligent Heat Panel Instrument, Jinan Yiyan Science & Technology Development Co., Ltd, Jinan, China) was used to measure the HWL to thermal stimulation. The hindpaw of the rat was placed manually on a hot plate which was maintained at 52°C (52 ± 0.2°C). The time to hindpaw withdrawal was measured to be referred to as the HWLs to thermal stimulation. Before intra-ACC injection, the HWL to thermal stimulation was measured as the basic threshold. To avoid tissue damage, a cut-off limit was set up of 15 s.

#### Inflammatory Pain Model

To induce inflammatory pain, rats received an intraplantar injection of 0.1 ml of (2%, 0.2 mg carrageenan in 0.1 ml saline,
Sigmoid (Sigma) carrageenan into the midplantar region of the left hindpaw. Behavioral experiments were performed during 3 to 4 h after carrageenan injection during the peak of the acute phase of the inflammatory response (Sun et al., 2003; Li et al., 2005).

**Lentiviral Transduction and Stereotactic Microinjection**

Knockdown of CLR expression in the ACC was mediated by lentivirus. The coding sequence was connected into the GV493 plasmid (Genechem, Shanghai, China). The siRNA sequence for CLR is 5′-ATGCAGGATCCCCATTCACAA-3′, whereas the sequence for the control siRNA is 5′-TTCTCGAAGCCTGTCACGT-3′. All correct insertions were confirmed by restriction mapping and direct DNA sequencing. Titers of concentrated viral particles were 8E + 8 TU/ml. Naïve rats were deeply anesthetized by intraperitoneal injections of pentobarbital sodium and the rat's head was fixed in a stereotaxic frame (Stoelting Co. Ltd., USA). One microliter of LV-CLR-RNAi and LV-control-RNAi were bilaterally microinjected into the ACC of rats over 10 min, and the needle was left for 10 min in situ (Wang P. et al., 2016).

**Quantitative Real-time Polymerase Chain Reaction (RT-PCR)**

RT-PCR was used for measuring the mRNA level of CLR in the ACC of rats. To compare the changes of CLR mRNA in ACC of naïve rats without injection of carrageenan (n = 6, as a control) and rats received injection of carrageenan (n = 6, 3 h after injection), an over dose of pentobarbital sodium was administered to the rat and the brain of the rat was removed. The right side ACC tissues, as the inflammatory pain in left hindpaw, were dissected and rapidly stored at −80°C. Total RNA was extracted from the ACC tissues by using the SPARKeasy Improved Tissue RNA kit (SparkJade, Qingdao, China). cDNA synthesis was performed by reverse transcription using the SPARKeasy Improved Tissue RNA kit (SparkJade, Qingdao, China). The StepOnePlus™ Real-Time PCR System with Tower (Applied Biosystems) and 2 SYBR Green qPCR Mix (SparkJade, Qingdao, China) were used to amplify CLR. For amplification of both CLR and the reference gene (glyceraldehyde 3-phosphate dehydrogenase, GAPDH), the following PCR protocol was applied: 94°C for 3 min, 94°C for 10 s, 60°C for 34 s, 40 cycles. The primers used were as follows: CLR primer sequences were forward 5′-AGAGCTTAAGTTGCCAACGG-3′; reverse 5′-CCACTGGCGTAGTTGAATG-3′; GAPDH primer sequences were forward 5′-GACCACCGACGCAGCAAGG-3′, reverse 5′-TCCCCAGGOCCTCTCTTGG-3′ (Zhang et al., 2017b).

**Western Blotting**

To compare the changes of CLR concentration in ACC of naïve rats (n = 6, control group) and rats with inflammation (n = 6, 3 h after carrageenan injection), an overdose of pentobarbital sodium was administered to the rat and the brain of the rat was removed. The right side ACC tissues, as the inflammatory pain in left hindpaw, were dissected and rapidly stored at −80°C. The ACC tissues were put on ice and homogenized with an Ultrasonic Crusher, and protein was extracted with RIPA lysis buffer and phenylmethylsulfonyl fluoride (Beyotime Institute of Biotechnology, Shanghai, China). Protein concentrations of the lysate were determined using Enhanced BCA Protein Assay Kit (Beyotime Institute of Biotechnology, Shanghai, China). The protein samples (30 µg) were loaded on 12% SDS-PAGE gel for 30 min, and migrated onto PVDF membranes for 60 min (Millpore, MA, USA). Membranes were blocked with 5% nonfat dry milk for 2 h at room temperature and incubated with polyclonal rabbit anti-CLR antibody (1:1,000 dilution; bs-1860R; RRID: AB_10855106; Bioss, Beijing, China) (Toriyama et al., 2015), beta-actin antibody (1:1,500 dilution; AA128; Beyotime Institute of Biotechnology, Shanghai, China) at 4°C for 1 night. The signal protein bands were detected by enhanced chemiluminescent reagents (Beyotime Institute of Biotechnology, Shanghai, China) and imaged by ImageQuant LAS 4000 (GE Healthcare Bio-Sciences AB, Tokyo, Japan), then analyzed by Gel-Pro Analyzer software (Media Cybernetics, Bethesda, MD, USA). The intensity of each blot band was calculated as a ratio to β-actin (Wang et al., 2019).

**Experimental Data Analysis**

All statistical analyses were performed with the IBM SPSS Statistics program (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp). Experimental data were presented as mean ± S.E.M. Figures were performed using GraphPad Prism 8. Statistical difference between two groups was determined by two-tailed Student’s t-test. One-way ANOVA analysis followed by the Bonferroni test was used for comparisons between multiple groups. In all cases, the criterion for statistical significance was P < 0.05, P ≥ 0.05 was considered non-significant difference.

**RESULTS**

**CGRP Induced Antinociception in ACC in Naïve Rats**

To observe the effect of CGRP in nociceptive regulation in ACC in naïve rats, four groups of naïve rats received different doses of CGRP in ACC: (1) 1 µl of 0.9% saline (as control, n = 8), (2) 0.1 nmol of CGRP (n = 8), (3) 0.5 nmol of CGRP (n = 8), or (4) 1 nmol of CGRP (n = 8). The behavioral test lasted for 60 min and the results at 30 min after injection of CGRP are shown in Figures 1A, B.

The HWLs of naïve rats to noxious thermal stimulation increased significantly in a dose-dependent manner after intra-
ACC injection of 0.1 nmol of CGRP (left HWL: P < 0.05; right HWL: P < 0.05), 0.5 nmol of CGRP (left HWL: P < 0.05; right HWL: P < 0.05), and 1 nmol of CGRP (left HWL: P < 0.05; right HWL: P < 0.05) compared with the control group (one-way ANOVA followed Bonferroni test).

To check the influence of the CGRP receptor antagonist CGRP8-37 on CGRP induced antinociception, four groups of rats received intra-ACC injection of 1 nmol of CGRP, followed 5 min later by intra-ACC injection of 0.1 nmol (n = 6), 0.5 nmol (n = 6), or 1 nmol of CGRP8-37 (n = 6), or 1 μl of 0.9% saline (n = 6) as a control. The changes in HWLs at 30 min after CGRP injection are shown in Figures 1C, D.

The HWLs to noxious thermal stimulation increased after CGRP injection. The HWLs decreased significantly after intra-ACC administration of 0.1 nmol of CGRP8-37 (left HWL: P ≥ 0.05; right HWL: P ≥ 0.05), 0.5 nmol of CGRP8-37 (left HWL: P < 0.05; right HWL: P < 0.05), and 1 nmol of CGRP8-37 (left HWL: P < 0.05; right HWL: P < 0.05) compared with the control group (one-way ANOVA followed Bonferroni test), as shown in Figures 1C, D.

Another group of rats received intra-ACC injection of 1 μl of 0.9% saline, followed 5 min later by intra-ACC injection of 1 nmol of CGRP8-37 (n = 6). There are no marked changes in HWLs to noxious thermal stimulation after the injection of CGRP8-37 (Figures 1C, D), indicating that there may be no endogenous CGRP release in ACC in normal condition.

The results demonstrated that intra-ACC injection of CGRP induced antinociceptive effects in naïve rats, and blockade CGRP receptor by CGRP8-37 attenuated the CGRP-induced antinociception in ACC, indicating that the CGRP-induced antinociception may be mediated by CGRP receptor in ACC of naïve rats.

Figure 2 shows the basal HWL (n = 8), HWL in rats received intra-ACC injection of 1 nmol of CGRP (n = 8), or HWL in rats received CGRP8-37 (n = 6). The HWLs to noxious thermal stimulation increased significantly after CGRP injection (left HWL: P < 0.05; right HWL: P < 0.05) compared with basal HWLs, while there were no significant changes in HWL after CGRP8-37 injection (left HWL: P ≥ 0.05; right HWL: P ≥ 0.05) compared to basal HWLs, as shown in Figures 2A, B.

**CGRP Induced Antinociception in ACC in Rats With Inflammatory Pain**

Rats received injection of carrageenan into the midplantar region of the left hindpaw to set up a model of inflammatory pain. The HWLs to noxious thermal were assessed by the hot-plate test before and after injection of carrageenan. The left HWLs decreased significantly at 3 h (P < 0.05, two-tailed student’s t-test. n = 7) and 4 h after carrageenan injection (P < 0.05, two-tailed student’s t-test. n = 7), as shown in Figure 3A.

To observe the influence of CGRP in ACC on nociceptive modulation in rats with inflammatory pain, four groups of rats

**FIGURE 1** | Intra-ACC injection of CGRP induced antinociception, an effect was inhibited by CGRP8-37 in naïve rats. Data show the results obtained at 30 min after CGRP injection. Hot plate test, (A, C), left HWL; (B, D), right HWL. Data are expressed as Mean ± S.E.M. and analyzed by one-way ANOVA followed Bonferroni test. Experimental data showed a significant difference from the control group (*P < 0.05).
received intra-ACC administration of 0.1 nmol (n = 7), 0.5 nmol (n = 7), or 1 nmol of CGRP (n = 7), or 1 μl of 0.9% saline as a control (n = 7). Figure 3B showed the changes in HWLs at 30 min after CGRP injection. The HWLs to noxious thermal stimulation increased significantly in a dose-dependent manner after intra-ACC injection of 0.1 nmol of CGRP (Hot-plate test: P < 0.05), 0.5 nmol of CGRP (Hot-plate test: P < 0.05), and 1 nmol of CGRP (Hot-plate test: P < 0.05) compared with the control group (one-way ANOVA followed Bonferroni test). The results demonstrated that intra-ACC injection of CGRP induced significant antinociceptive effects in rats with inflammatory pain.

Two groups of rats with inflammatory pain received intra-ACC injection of 1 nmol of CGRP, followed 5 min later by intra-ACC injection of 1 nmol of CGRP8-37 (n = 6), or 1 μl of 0.9% saline (n = 6) as a control. The results showed the changes of HWLs at 30 min after CGRP injection. As shown in Figure 3C, the HWLs decreased significantly after intra-ACC administration of 1 nmol of CGRP8-37 (Hot-plate test: P < 0.05. two-tailed student’s t-test) compared with the control group. The results demonstrated that blockade CGRP receptor by CGRP8-37 attenuated the CGRP-induced antinociception in ACC, indicating that the CGRP-induced antinociception may be mediated by CGRP receptor in ACC of rats with inflammatory pain.

Another group of rats received intra-ACC injection of 1 μl of 0.9% saline, followed 5 min later by intra-ACC injection of 1
nmol of CGRP8-37 (n = 7). There are no marked changes in HWLs to noxious thermal stimulation after the injection of CGRP8-37. The results are shown in Figure 3C.

**Influence of Inflammatory Pain on the CGRP-Induced Antinociception and CGRP Receptor Expression in ACC**

Figure 4A shows the basal HWL to noxious thermal stimulation in naïve rats and rats with inflammatory pain. The left basal HWL was significantly decreased in rats with inflammatory pain (n = 8) than that in naïve rats (n = 8) (Hot-plate Test: P < 0.05; Randall Selitto Test: P < 0.05, two-tailed student’s t-test).

We further compared the changes of CGRP-induced antinociception in ACC in naïve rats (n = 8) and rats with inflammatory pain (n = 8). As shown in Figure 4A, CGRP induced increases in HWLs to noxious thermal stimulation in both naïve rats and rats with inflammatory pain. Interestingly, the CGRP-induced increase in HWLs to noxious thermal stimulation was significantly lower in rats with inflammatory pain compared to naïve rats, as shown in Figure 4B (Hot plate test: P < 0.05; two-tailed student’s t-test).

To explore why the CGRP-induced antinociception was lower during inflammatory pain than that in naïve rats, we checked the change of CGRP receptor expression in ACC in rats with inflammatory pain. As the CLR is the main component of CGRP receptor, the CLR expression was checked in ACC in rats with inflammatory pain.

The mRNA levels of CLR in ACC of naïve rats (n = 6) and rats with inflammatory pain (n = 6) were determined by RT-PCR. The results are shown in Figure 5A. It was found that there was a significant decrease in the mRNA levels of CLR (P < 0.05, Student’s t-test) in ACC in rats with inflammatory pain than that in naïve rats, indicating a decrease in CGRP expression in ACC during inflammatory pain.

The concentration of CLR protein in ACC of naïve rats (n = 6) and rats with inflammatory pain (n = 6) were further determined by western blotting. The results showed that there was also a significant decrease in the concentration of CLR protein (P < 0.05, two-tailed student’s t-test) in ACC in rats with inflammatory pain than that in naïve rats, as shown in Figures 5B, C.

The results suggest that there is a decrease in CGRP receptor expression in ACC in rats with inflammatory pain, which may
inhibit the CGRP-induced antinociception in ACC in rats with inflammatory pain.

Influence of siRNA Targeting CLR on the CLR mRNA Level and the CLR Protein Concentration in ACC

In order to confirm that decrease in CGRP receptor expression in ACC inhibits CGRP-induced antinociception, three groups of rats received intra-ACC injection of siRNA targeting CLR (n = 6), intra-ACC injection of CLR scrambled-siRNA (n = 6), or rats without injection of siRNA (n = 6). The mRNA levels of CLR in ACC were measured by RT-PCR and the results are shown in Figure 6A.

As shown in Figure 6A, there was a significant decrease in the mRNA levels of CLR (P < 0.05, one-way ANOVA followed Bonferroni test) in ACC rats with 3 days after intra-ACC injection of siRNA targeting CLR than that in rats with intra-ACC injection of the scrambled siRNA. However, the mRNA level of CLR showed no significant change (P ≥ 0.05, one-way ANOVA followed Bonferroni test) in ACC in rats with intra-ACC injection of scrambled siRNA compared to rats without injection of siRNA. The results demonstrated that the CLR mRNA levels decreased significantly after intra-ACC administration of siRNA targeting CLR.

To further confirm the above siRNA results, western blotting was used. Three groups of rats received intra-ACC injection of siRNA targeting CLR (n = 6), intra-ACC injection of CLR scrambled-siRNA (n = 6), or rats without injection of siRNA (n = 6). The results are shown in Figures 6B, C.

There was a significant decrease in the concentration of CLR in ACC in rats with injection of siRNA targeting CLR than that in rats with injection of scrambled siRNA (P < 0.05, one-way ANOVA followed Bonferroni test) tested by western blotting. There was no significant change in the concentration of CLR in ACC in rats with intra-ACC injection of scrambled siRNA compared to rats without injection of siRNA (P ≥ 0.05, one-way ANOVA followed Bonferroni test). These results demonstrated that intra-ACC injection of siRNA targeting CLR inhibited CLR expression in ACC, suggesting that the expression of CGRP receptor decrease after intra-ACC injection of siRNA targeting CLR.

Influence of Knockdown CLR on the CGRP-Induced Antinociception in ACC

We further checked the influence of intra-ACC injection of siRNA targeting CLR on basal HWLs and CGRP-induced antinociception. Two groups of naïve rats received intra-ACC injection of siRNA targeting CLR (n = 7), intra-ACC injection of scrambled-siRNA (n = 6) as a control. Three days later, the basal HWLs of rats and rats received intra-ACC administration of 1 nmol of CGRP. The results are shown in Figure 7.

The HWLs to thermal stimulation increased significantly after CGRP injection. Interestingly, the CGRP-induced antinociception to noxious thermal stimulation was significant lower in rats with intra-ACC injection of siRNA targeting CLR (left HWL: P < 0.05; right HWL: P < 0.05. two-tailed student’s t-test) compared to rats with intra-ACC scrambled siRNA. These results suggested that knockdown CGRP receptor expression in ACC attenuated the CGRP-induced antinociception.

DISCUSSIONS

In the present study, we found that intra-ACC administration of CGRP induced significant antinociceptive effects in a dose-dependent manner in both naïve rats and rats with inflammatory pain. Recent studies have consistently demonstrated that long-term potentiation is a key cellular mechanism for chronic pain in the ACC. The study found that CGRP induced potentiation of synaptic transmission in a dose-dependently manner and CGRP8-37 blocked the CGRP-induced long term potentiation in ACC (Li et al., 2019). In our study, we found that intra-ACC administration of CGRP induced significant antinociceptive effects in a dose-dependent manner in both naïve rats and rats with inflammatory pain. And we found that CGRP8-37 attenuate the CGRP-induced antinociception in
ACC, indicating that the CGRP-induced antinociception may be mediated by CGRP receptor in ACC of rats. So CGRP induced potentiation of synaptic transmission is very likely to be related to CGRP induced significant antinociceptive effects.

Therefore the antinociceptive activity of i.c.v. administered CGRP might be an effect of the peptide on the ACC that ultimately inhibit nociceptive transmission at the spinal cord by activating descending antinociceptive pathways. To determine the involvement of CGRP receptor in CGRP-induced antinociception in ACC, the selective CGRP receptor antagonist CGRP8-37 was used (Chiba et al., 1989; Adwanikar et al., 2007; Yu et al., 2009; Alexander et al., 2011) and found that CGRP8-37 attenuate the CGRP-induced antinociception in ACC, indicating that the CGRP-induced antinociception may be mediated by CGRP receptor in ACC of rats. CGRP also can activate amylin receptor (Hay et al., 2018). As amylin receptor is not sensitive to CGRP8-37 (Hay et al., 2008; Yu et al., 2009), our results showed that the CGRP-induced antinociception was mediated by CGRP receptor in ACC as the effect was attenuated by following administration of CGRP8-37. The results strongly indicated that it was CGRP receptor, not amylin receptor as it not sensitive to CGRP8-37 (Hay et al., 2008; Yu et al., 2009), was activated by CGRP to induce antinociception in ACC. Furthermore, CGRP receptor was knockdown in ACC and found that the CGRP-induced antinociception decreased significantly. Combine our pharmacological results, the CGRP receptor plays a main role in CGRP-induced antinociception in ACC.

The present study further found that the CGRP-induced antinociception was lower in ACC in rats with inflammatory pain compared with that in naïve rats. To answer why the CGRP-induced antinociception was lower in ACC in rats with inflammatory pain, we applied siRNA targeting CLR into ACC and found that both mRNA level of CLR and CLR concentration decreased in ACC compared to into ACC, indicating a down regulation of CLR expression in ACC. Interestingly, the CGRP-induced antinociception was significant lower in rats with intra-ACC siRNA targeting CLR compared to rats with injection of scrambled siRNA. These results further confirm that decrease of CGRP receptor expression in ACC also attenuates the CGRP-induced antinociception.

CONCLUSIONS

In conclusions, our findings indicate that CGRP and CGRP receptor play an important role in nociceptive modulation in ACC, inhibiting CGRP receptor expression induces decrease in CGRP-induced antinociception in ACC.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of the Yantai University Yantai University.
AUTHOR CONTRIBUTIONS

K-SH completed the whole experiment and wrote the manuscript. L-LW performed part of the behavioral test, H-BW edited the manuscript, F-HF and L-CY designed the experiments and edited the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

Adwanikar, H., Ji, G. G., Li, W. D., Doods, H., Willis, W. L., and Neugebauer, V. (2007). Spinal CGRP1 receptors contribute to supraspinally organized behavior and pain-related sensitization of amygdala neurons. Pain. 132, 53–66. doi: 10.1016/j.pain.2007.01.024

Alexander, S. P., Mathie, A., and Peters, J. A. (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br. J. Pharmacol. 164(Suppl 1), S1–S24. doi: 10.1111/j.1476-5381.2011.01649_1.x

Bliss, T. V., Collingridge, G. L., Kaang, B. K., and Zhuo, M. (2016). Synaptic plasticity in the anterior cingulate cortex in acute and chronic pain. Rev. Neurol. 170, 485–496. doi: 10.1016/r.rrev.2016.06.68

Bullock, C. M., and Kelly, S. (2013). Calcitonin gene-related peptide receptors: antagonists beyond migraine—a possible analgesic strategy for osteoarthritis? Curr. Pain Headache Rep. 17, 375–386. doi: 10.1007/s11916-013-0375-2

Chiba, T., Yamaguchi, A., Yamatani, T., Nakamura, A., Morishita, T., Inui, T., et al. (1989). Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am. J. Physiol. 256, E331–E335. doi: 10.1152/ajpendo.1989.256.E331

Edvinsson, L. (2008). CGRP blockers in migraine therapy: where do they act? Br. J. Pharmacol. 153, 967–969. doi: 10.1016/bjp.2008.3.46

Edvinsson, L. (2017). The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache. 57 suppl 2, 47–55. doi: 10.1111/head.13081

Gu, L., Uhelski, M. L., Anand, S., Romero-Ortega, M., Kim, Y., and Fuchs, P. N. (2015). Samarendra K Mohanty et al, Pain inhibition by optogenetic activation of specific anterior cingulate cortical neurons. PLoS One 10, e0117746. doi: 10.1371/journal.pone.0117746

Han, J. S., Adwanikar, H., Li, Z., Ji, G., and Neugebauer, V. (2010). Facilitation of synaptic transmission and pain responses by CGRP in the amygdala of normal rats. Mol. Pain. 6, 10. doi: 10.1086/17448069-6-10

Harris-Bozer, A. L., and Peng, Y. B. (2016). Inflammatory pain by carrageenan recruits low-frequency local field potential changes in the anterior cingulate cortex. Neurosci. Lett. 632, 8–14. doi: 10.1016/j.neulet.2016.08.016

Hay, D. L., and Walker, C. S. (2017). CGRP and its receptors. Headache. 57, 625–636. doi: 10.1111/head.13064

Hay, D. L., Poyner, D. R., and Quirion, R. (2008). International Union of P. International Union of Pharmacology. LXXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol. Rev. 60, 143–145. doi: 10.1124/pr.100.00372

Hay, D. L., Garejla, M. L., Poyner, D. R., and Walker, C. S. (2018). Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br. J. Pharmacol. 175, 3–17. doi: 10.1111/bph.14075

Iyengar, S., Osipov, M. V., and Johnson, K. W. (2017). The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 158, 543–559. doi: 10.1010/j.pain.2016.08.0031

Kilkenny, C., Browne, M. W., Cuthill, I. C., Emerson, M., and Altman, D. G. (2010). Aute standards for reporting experimental animal research: ARRIVE etc.: new requirements for publication in the International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev. 94, 1099–1142. doi: 10.1152/physrev.00034.2013

Shen, F. Y., Chen, Z. Y., Zhong, W., Ma, L. Q., Chen, C., Yang, Z. J., et al. (2015). Alleviation of neuropathic pain by regulating T-type calcium channels in rat anterior cingulate cortex. Mol. Pain. 11, 7. doi: 10.1186/s12990-015-0008-3

Sun, Y. G., Gu, X. L., Lundeberg, T., and Yu, L. C. (2003). An antinociceptive role of galanin in the accumbus nucleus of hypothalamus in intact rats and rats with inflammation. Pain. 106, 143–150. doi: 10.1016/j.pain.2004.08.0065

Tepper, S. J. (2019). CGRP and headache: a brief review. Neurol. Sci. 40, 99–105. doi: 10.1007/s10072-019-03769-8

Tomic, M., Pecikoza, U., Micov, A., Vuckovic, S., and Stepanovic-Petrovic, R. (2018). Antiepileptic drugs as analgesics/adjuvants in inflammatory pain: current preclinical evidence. Mol. Pharm. Ther. 19, 42–64. doi: 10.1016/j.mpt.2018.06.002

Toniyama, Y., Iszato, Y., Imai, A., Sakurai, T., Kamiyoshi, A., Ichikawa-Shindo, Y., et al. (2015). Pathophysiological function of endogenous calcitonin gene-related peptide in ocular vascular diseases. Am. J. Pathol. 185, 1783–1794. doi: 10.1161/apjpath.2015.02.017

Tsuda, M., Koga, K., Chen, T., and Zhuo, M. (2017). Neuronal and microglial mechanisms for neuropathic pain in the spinal dorsal horn and anterior cingulate cortex. J. Neurochem. 141, 486–498. doi: 10.1111/jnc.14001

Wang, P., Li, H., Barde, S., Zhang, M. D., Sun, J., Wang, T., et al. (2016). Alleviation of spreading depression. Proc. Natl. Acad. Sci. U. S. A. 113, E4726–E4735. doi: 10.1073/pnas.1609198113

Wang, Y., Li, Y., and Wang, M. (2016). Involvement of CGRP receptors in retinal spreading depression. Pharmacol. Rep. 68, 935–938. doi: 10.1016/j.pharep.2016.05.001

Wang, L. L., Hou, K. S., Wang, H. B., Fu, F. H., and Yu, L. C. (2019). Role of mu-opioid receptor in nociceptive modulation in the anterior cingulate cortex of rats with inflammatory pain. J. Clin. Exp. Pharmacol. 9, 259. doi: 10.4172/2161-1459.1000259

Warfvinge, K., and Edvinsson, L. (2019). Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia. 39, 342–353. doi: 10.1177/0333102417728873

Xu, H., Wu, L. J., Wang, H., Zhong, X., Vadakkann, K. L., Kim, S. S., et al. (2008). Presynaptic and postsynaptic amplifications of neuropathic pain in the

ACKNOWLEDGMENTS

The study is supported by grants from Foundation of Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong (Yantai University), the Graduate Innovation Foundation of Yantai University, and the National Natural Science Foundation of China (NSFC 81171043).

Li, S., Han, J., Wang, D. S., Yang, Q., Feng, B., Kang, W. B., et al. (2017). Simomine attenuates chronic inflammatory pain in mice. Metab. Brain Dis. 32, 211–219. doi: 10.1007/s11011-016-9889-8

Li, X. H., Matsuura, T., Liu, R. H., Xue, M., and Zhuo, M. (2019). Calcitonin gene-related peptide potentiated the excitatory transmission and network propagation in the anterior cingulate cortex of adult mice. Mol. Pain. 15, 1744806919327817. doi: 10.1177/1744806919327817

Lu, B., Jiang, J., Sun, J., Xiao, C., Meng, B., Zheng, J., et al. (2016). Inhibition of mammalian target of rapamycin activation in the rostral anterior cingulate cortex attenuates pain-related aversion in rats. Behav. Brain Res. 310, 51–58. doi: 10.1016/j.bbr.2016.05.031
anterior cingulate cortex. *J. Neurosci.* 28, 7445–7453. doi: 10.1523/JNEUROSCI.1812-08.2008
Yu, L. C., Weng, X. H., Wang, J. W., and Lundeberg, T. (2003). Involvement of calcitonin gene-related peptide and its receptor in anti-nociception in the periaqueductal grey of rats. *Neurosci. Lett.* 349, 1–4. doi: 10.1016/S0304-3940(03)00273-8
Yu, L. C., Hou, J. F., Fu, F. H., and Zhang, Y. X. (2009). Roles of calcitonin gene-related peptide and its receptors in pain-related behavioral responses in the central nervous system. *Neurosci. Biobehav. Rev.* 33, 1185–1191. doi: 10.1016/j.neubiorev.2009.03.009
Zhang, M. L., Fu, F. F., and Yu, L. C. (2017a). Antinociception induced by galanin in anterior cingulate cortex in rats with acute inflammation. *Neurosci. Lett.* 638, 156–161. doi: 10.1016/j.neulet.2016.12.034
Zhang, M. L., Wang, H. B., Fu, F. H., and Yu, L. C. (2017b). Involvement of galanin and galanin receptor 2 in nociceptive modulation in anterior cingulate cortex of normal rats and rats with mononeuropathy. *Sci. Rep.* 7, 45930. doi: 10.1038/srep45930
Zhuo, M. (2006). Molecular mechanisms of pain in the anterior cingulate cortex. *J. Neurosci.* 84, 927–933. doi: 10.1002/jnr.21003
Zhuo, M. (2008). Cortical excitation and chronic pain. *Trends Neurosci.* 31, 199–207. doi: 10.1016/j.tins.2008.01.003

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hou, Wang, Wang, Fu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.